The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Valuation Is Forecasted For The Familial Amyloid Polyneuropathy Market By 2030 Starting From Its 2026 Size?
The market for familial amyloid polyneuropathy has experienced robust expansion in recent years. Projections indicate it will expand from $1.65 billion in 2025 to $1.79 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 8.3%. Historically, this growth is linked to factors such as improved rare disease diagnosis, increased genetic disorder awareness, advancements in transplant medicine, focused neurology research, and wider adoption of supportive care.
The market size for familial amyloid polyneuropathy is projected to undergo substantial expansion in the coming years. By 2030, this market is anticipated to reach a valuation of $2.43 billion, exhibiting a compound annual growth rate (CAGR) of 8.0%. This forecasted growth is primarily driven by factors such as innovation in gene therapy, the increase in early genetic testing, enhanced funding for rare diseases, the widespread adoption of precision medicine, and the continued growth of specialty pharmacies. Significant trends for the forecast period include the increasing adoption of TTR stabilizers, the broader expansion of gene silencing therapies, a rise in genetic screening initiatives, a heightened focus on rare disease treatment, and the development of specialty care centers.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24532&type=smp
What Drivers Are Shaping The Future Growth Of The Familial Amyloid Polyneuropathy Market?
The escalating emphasis on gene therapy is anticipated to stimulate the expansion of the familial amyloid polyneuropathy market moving forward. Gene therapy is a therapeutic approach that works by modifying or replacing faulty genes to address the root cause of illnesses. This treatment method is gaining traction as it targets and corrects defective genes, offering lasting or permanent cures rather than merely alleviating symptoms. For familial amyloid polyneuropathy, gene therapy focuses on correcting or silencing the abnormal transthyretin (TTR) gene, thereby preventing the formation of harmful amyloid protein. This intervention aids in reducing amyloid deposits, which slows disease progression and helps preserve nerve function. For instance, in July 2023, according to the American Society of Gene & Cell Therapy (ASGCT), a US-based professional membership organization, and Citeline, a US-based provider of drugs and devices, there were 247 gene therapies in Phase II at the end of the first quarter of 2023, a number that subsequently increased by 5% to reach 260 by the end of the second quarter. Thus, the increasing focus on gene therapy is acting as a catalyst for the growth of the familial amyloid polyneuropathy market.
Which Segment Categories Define The Familial Amyloid Polyneuropathy Market?
The familial amyloid polyneuropathy market covered in this report is segmented –
1) By Treatment: Medication, Gene Therapy, Supportive Care, Pain Management, Symptomatic Treatment
2) By Diagnosis: Genetic Testing, Biopsy, Imaging, Other Diagnosis
3) By Patient Age Group: Pediatric, Adult, Geriatric
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Pharmacies, Direct Sales
5) By End-User: Hospitals, Specialty Clinics, Research Institutes, Other End-Users
Subsegments:
1) By Medication: Transthyretin (TTR) Stabilizers, Transthyretin (TTR) Gene Silencers, Tafamidis, Diflunisal, Patisiran
2) By Gene Therapy: Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Or Cas9-Based Therapy, RNA Interference (RNAi) Therapy, Antisense Oligonucleotides (ASO) Therapy
3) By Supportive Care: Physical Therapy, Occupational Therapy, Nutritional Support, Psychological Counseling
4) By Pain Management: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Opioids, Antidepressants, Anticonvulsants
5) By Symptomatic Treatment: Gastrointestinal Symptom Management, Cardiovascular Symptom Management, Autonomic Dysfunction Management, Orthostatic Hypotension Treatment
What Major Market Trends Are Driving Changes In The Familial Amyloid Polyneuropathy Market?
Key companies within the familial amyloid polyneuropathy market are concentrating on developing advanced treatment solutions, such as RNA interference (RNAi) therapeutics, to slow the progression of the disease and improve patient outcomes. RNA interference (RNAi) therapeutics represent advanced treatments that effectively silence disease-causing genes by targeting their messenger RNA (mRNA). This approach serves to block the production of harmful proteins, thereby addressing genetic diseases at their fundamental origin. For instance, in March 2025, Alnylam Pharmaceuticals, a US-based biopharmaceutical company, introduced AMVUTTRA (vutrisiran), which had received approval from the Food and Drug Administration (FDA) for treating cardiomyopathy linked to wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults. It is administered through four subcutaneous doses per year and is specifically designed to treat both ATTR-CM and the polyneuropathy associated with hereditary transthyretin-mediated amyloidosis (hATTR-PN). By reducing the production of transthyretin (TTR) protein, which is the root cause of the disease, it significantly lowers cardiovascular mortality, hospitalizations, and urgent heart failure visits, as evidenced in the HELIOS-B Phase 3 clinical trial.
Who Are The Top Companies Competing In The Familial Amyloid Polyneuropathy Market?
Major companies operating in the familial amyloid polyneuropathy market are Pfizer Inc., AstraZeneca plc, Novo Nordisk A/S, Regeneron Pharmaceuticals Inc., NYU Langone Hospitals, Alexion Pharmaceuticals Inc., Mount Sinai Medical Center, PTC Therapeutics Inc., Mayo Foundation for Medical Education and Research, Arcturus Therapeutics Inc., Precision BioSciences Inc., Creative Biolabs, Stanford Health Care, Duke University Health System, YolTech Therapeutics
Read the full familial amyloid polyneuropathy market report here:
Which Geographic Regions Are Influencing Demand In The Familial Amyloid Polyneuropathy Market?
North America was the largest region in the familial amyloid polyneuropathy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the familial amyloid polyneuropathy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Familial Amyloid Polyneuropathy Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=24532&type=smp
Browse Through More Reports Similar to the Global Familial Amyloid Polyneuropathy Market 2026, By The Business Research Company
Peripheral Neuropathy Market Report 2026
https://www.thebusinessresearchcompany.com/report/peripheral-neuropathy-global-market-report
Transthyretin Amyloidosis Treatment Market Report 2026
Diabetic Neuropathy Market Report 2026
https://www.thebusinessresearchcompany.com/report/diabetic-neuropathy-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model